Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma
Blood · 2023
DOI: 10.1182/blood.2022019166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Zhihui Song und 14 weiteren Autor:innen. Beteiligte Einrichtung: Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Anaplastic large cell lymphoma (ALCL), a subgroup of mature T-cell neoplasms with an aggressive clinical course, is characterized by elevated expression of CD30 and anaplastic cytology. To achieve a comprehensive understanding of the molecular characteristics of ALCL pathology and to identify therapeutic vulnerabilities, we applied genome-wide CRISPR library screenings to both anaplastic lymphoma kinase positive (ALK+) and primary cutaneous (pC) ALK− ALCLs and identified an unexpected role of the interleukin-1R (IL-1R) inflammatory pathway in supporting the viability of pC ALK− ALCL. Importantly, this pathway is activated by IL-1α in an autocrine manner, which is essential for the induction and maintenance of protumorigenic inflammatory responses in pC-ALCL cell lines and primary cases. Hyperactivation of the IL-1R pathway is promoted by the A20 loss-of-function mutation in the pC-ALCL lines we analyze and is regulated by the nonproteolytic protein ubiquitination network. Furthermore, the IL-1R pathway promotes JAK-STAT3 signaling activation in ALCLs lacking STAT3 gain-of-function mutation or ALK translocation and enhances the sensitivity of JAK inhibitors in these tumors in vitro and in vivo. Finally, the JAK2/IRAK1 dual inhibitor, pacritinib, exhibited strong activities against pC ALK− ALCL, where the IL-1R pathway is hyperactivated in the cell line and xenograft mouse model. Thus, our studies revealed critical insights into the essential roles of the IL-1R pathway in pC-ALCL and provided opportunities for developing novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA.
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
- Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA.
- Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Department of Pathology and Laboratory Medicine, Brown University Alpert School of Medicine, Providence, RI.
- Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
ORCID-Profile: Wei Wei, Kathy Q Cai, Subin Jeong, Marshall E Kadin, Masao Nakagawa, Yibin Yang
Förderung
- NCI NIH HHS
Zitieren
APA
Song, Z., Wu, W., Wei, W., Xiao, W., Lei, M., Cai, K. Q., Huang, D. W., Jeong, S., Zhang, J. P., Wang, H., Kadin, M. E., Waldmann, T. A., Staudt, L. M., Nakagawa, M., & Yang, Y. (2023). Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma. Blood. https://doi.org/10.1182/blood.2022019166
Vancouver
Song Z, Wu W, Wei W, Xiao W, Lei M, Cai KQ, et al. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma. Blood. 2023. doi:10.1182/blood.2022019166
BibTeX
@article{Song2023,
author = {Song, Zhihui and Wu, Wenjun and Wei, Wei and Xiao, Wenming and Lei, Michelle and Cai, Kathy Q and Huang, Da Wei and Jeong, Subin and Zhang, Jing-Ping and Wang, Hongbo and Kadin, Marshall E and Waldmann, Thomas A and Staudt, Louis M and Nakagawa, Masao and Yang, Yibin},
title = {Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022019166}
}
EUVIMED